177lu-psma-617
novartis
['pcsm', ' vision']
all subgroups based on prior or concurrent treatment appear to derive similar benefit from lutetium psma #asco2022 #pcsm in vision trial 
An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family